CD38 Antibody (BLR123H)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14707
Recombinant Monoclonal Antibody
Key Product Details
Species Reactivity
Human
Applications
Multiplex Immunofluorescence, Immunohistochemistry, Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit Clone # BLR123H
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
residues 43-300 (ECD)
Clonality
Monoclonal
Host
Rabbit
Scientific Data Images for CD38 Antibody (BLR123H)
Western Blot: CD38 Antibody (BLR123H) [NBP3-14707] -
Detection of human CD38 by western blot.Samples: Whole cell lysate (10 ug) from HeLa, HEK293T, Jurkat, MOLT-4, RPMI-8226, CCRF-CEM, A-549, Ramos, Raji, and KG-1 cells prepared using NETN lysis buffer. Antibody: Rabbit anti-CD38 recombinant monoclonal antibody [BLR123H] (NBP3-14707 lot 1) used at 1:1000. Secondary: HRP-conjugated goat anti-rabbit IgG (A120-101P). Detection: Chemiluminescence with an exposure time of 10 seconds. Lower Panel: Rabbit anti-COPB2 antibody.
Western Blot: CD38 Antibody (BLR123H) [NBP3-14707] -
Detection of human CD38 by western blot of immunoprecipitates.Samples: Whole cell lysate (1.0 mg per IP reaction; 2% of IP loaded) from Ramos cells prepared using NETN lysis buffer. Antibodies: Rabbit anti-CD38 recombinant monoclonal antibody [BLR123H] (NBP3-14707 lot 1) used for IP at 20 ul/mg lysate. CD38 was also immunoprecipitated by rabbit anti-CD38 antibody BL1874B-2A3. For blotting immunoprecipitated CD38, NBP3-14707 was used at 1:1000. Detection: Chemiluminescence with an exposure time of 75 seconds.
Immunohistochemistry: CD38 Antibody (BLR123H) [NBP3-14707] -
Detection of human CD38 in FFPE colon carcinoma by immunohistochemistry.Antibody: Rabbit anti-CD38 recombinant monoclonal antibody [BLR123H] (NBP3-14707 Lot 1). Secondary: HRP-conjugated goat anti-rabbit IgG . Substrate: DAB.
Applications for CD38 Antibody (BLR123H)
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Multiplex Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
>95%
Formulation
Borate Buffered Saline (BBS) pH 8.2 with 0.1% BSA and
Preservative
0.09% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 2 - 8 C / 1 year from date of receipt
Background: CD38
As described above, CD38 is highly expressed in plasma cells and, as a result, is a target for treating multiple myeloma (MM), the cancer of white blood cells (4,6). The anti-CD38 monoclonal antibody daratumumab is one specific treatment for MM (4,6). Daratumumab has been shown to target MM cells through antibody-dependent cellular cytotoxicity and antibody dependent cellular phagocytosis (4). Additionally, CD38 has a potential role in neurodegenerative disorders and neuroinflammation as elucidated CD38's high expression in neurons, astrocytes, and microglia along with its enzymatic role in NAD degradation (3). Reduced NAD levels is a consequence of aging and occurs during neurodegeneration (3). Furthermore, murine studies have found that CD38 deletion inhibits neuroinflammation and neurodegeneration and therefore might be a potential therapeutic target (3). Similarly, CD38 inhibitors, like quercetin and luteolin, are used to treat age-related diseases and metabolic disorders (7).
References
1. Malavasi, F., Funaro, A., Alessio, M., DeMonte, L. B., Ausiello, C. M., Dianzani, U., Lanza, F., Magrini, E., Momo, M., & Roggero, S. (1992). CD38: a multi-lineage cell activation molecule with a split personality. International journal of clinical & laboratory research. https://doi.org/10.1007/BF02591400
2. Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008). Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiological reviews. https://doi.org/10.1152/physrev.00035.2007
3. Guerreiro, S., Privat, A. L., Bressac, L., & Toulorge, D. (2020). CD38 in Neurodegeneration and Neuroinflammation. Cells. https://doi.org/10.3390/cells9020471
4. van de Donk, N., Richardson, P. G., & Malavasi, F. (2018). CD38 antibodies in multiple myeloma: back to the future. Blood. https://doi.org/10.1182/blood-2017-06-740944
5. Lund, F. E., Cockayne, D. A., Randall, T. D., Solvason, N., Schuber, F., & Howard, M. C. (1998). CD38: a new paradigm in lymphocyte activation and signal transduction. Immunological reviews. https://doi.org/10.1111/j.1600-065x.1998.tb01573.x
6. Glaria, E., & Valledor, A. F. (2020). Roles of CD38 in the Immune Response to Infection. Cells. https://doi.org/10.3390/cells9010228
7. Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell metabolism. https://doi.org/10.1016/j.cmet.2018.02.011
Long Name
Cluster of Differentiation 38
Alternate Names
ADP-ribosyl Cyclase, CD38, Cyclic ADP-ribose Hydrolase
Gene Symbol
CD38
Additional CD38 Products
Product Documents for CD38 Antibody (BLR123H)
Product Specific Notices for CD38 Antibody (BLR123H)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...